[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100489602":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":33,"centralContacts":38,"locations":47,"responsibleParty":66,"collaborators":68,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":28,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":50,"whyStopped":28,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"University of Helsinki","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"p53 abn subtype and nonendometrioid carcinomas","EXPERIMENTAL","p53 abn stage I-II MI (myometrial invasion) \\>0%; MMR-D\u002FNSMP nonendometrioid stage I-II MI \\>0%",[13],"Other: Comparison of chemotherapy vs. chemoradiotherapy",{"label":15,"type":10,"description":16,"interventionNames":17},"MMR-D molecular subgroup","MMR-D stage IA-B grade 1-2, substantial LVSI; MMR-D stage IA grade 3, substantial LVSI; MMR-D stage IB grade 3; MMR-D stage II grade 1-3;",[18],"Other: Comparison of VBT vs. WPRT",{"label":20,"type":10,"description":21,"interventionNames":22},"NSMP molecular subgroup","NSMP stage IA-B grade 1-2, substantial LVSI; NSMP stage IA grade 3, substantial LVSI; NSMP stage IB grade 3; NSMP stage II grade 1-3;",[18],[24,29],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"Comparison of chemotherapy vs. chemoradiotherapy","Chemotherapy (paclitaxel-carboplatin) vs. chemoradiotherapy (paclitaxel-carboplatin followed by whole pelvic radiotherapy)\n\nPatients assigned to chemotherapy receive paclitaxel (175 mg\u002Fm2) and carboplatin (area under curve, 5) every 3 weeks for 6 cycles. The pelvic radiotherapy dose is 45 to 50.4 Gy over 5 to 6 weeks (1.8 Gy per day for 25 to 28 fractions).",[9],null,{"type":6,"name":30,"description":31,"armGroupLabels":32,"otherNames":28},"Comparison of VBT vs. WPRT","Vaginal brachytherapy vs. whole pelvic radiotherapy\n\nPatients randomized to vaginal brachytherapy receive cuff brachytherapy at 21 Gy in 3 fractions of 7 Gy at 0.5 cm depth. The pelvic radiotherapy dose is 45 to 50.4 Gy over 5 to 6 weeks (1.8 Gy per day for 25 to 28 fractions).",[15,20],[34],{"name":35,"affiliation":36,"role":37},"Mikko Loukovaara","Helsinki University Central Hospital","PRINCIPAL_INVESTIGATOR",[39,43],{"name":35,"role":40,"phone":41,"phoneExt":28,"email":42},"CONTACT","+358504272526","mikko.loukovaara@hus.fi",{"name":44,"role":40,"phone":45,"phoneExt":28,"email":46},"Ralf Bützow","+358504271899","ralf.butzow@hus.fi",[48],{"facility":49,"status":50,"city":51,"state":28,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Helsinki University Hospital","RECRUITING","Helsinki","00290","Finland","FI",{"type":56,"coordinates":57},"Point",[58,59],24.93545,60.16952,{"lat":59,"lon":58},[62,64],{"name":63,"role":40,"phone":41,"phoneExt":28,"email":42},"Mikko Loukovaara, MD",{"name":65,"role":40,"phone":45,"phoneExt":28,"email":46},"Ralf Bützow, MD",{"type":37,"investigatorFullName":35,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"Chief of Specialists, MD",[69,72,74,76,78,80,82],{"name":70,"class":71},"Turku University Hospital","OTHER_GOV",{"name":73,"class":6},"Tampere University Hospital",{"name":75,"class":6},"Kuopio University Hospital",{"name":77,"class":6},"Oulu University Hospital",{"name":79,"class":6},"Kymenlaakso Central Hospital Kotka Finland",{"name":81,"class":6},"Päijänne Tavastia Central Hospital",{"name":83,"class":6},"South Carelia Central Hospital","100489602","personalized-treatment-for-endometrial-carcinoma-100489602",false,"NCT05655260","PErsonalized TReatment for Endometrial Carcinoma","PETREC","Inclusion Criteria:\n\n* Age 18 to 100 years\n* WHO performance status 0 to 2\n* Stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma\n\nExclusion Criteria:\n\n* Age \\\u003C18 years or \\>100 years\n* WHO performance status \\>2\n* Uterine sarcoma\n* A history of malignancy within 5 years\n* Previous pelvic radiotherapy\n* An interval of \\>30 days between surgery and start of chemotherapy or \\>8 weeks between surgery and start of radiotherapy (longer intervals may be permitted with investigator´s approval)","FEMALE","18 Years","100 Years",{"count":95,"type":96},300,"ESTIMATED","INTERVENTIONAL",[99],"NA","The goal of this clinical trial is to compare the efficacy of adjuvant therapies in women with stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma. Specifically, the invesigators want to compare:\n\n* Chemotherapy vs. chemoradiotherapy in p53 abn subtype and nonendometrioid carcinomas.\n* Vaginal brachytherapy vs. whole pelvic radiotherapy in the MMR-D molecular subgroup.\n* Vaginal brachytherapy vs. whole pelvic radiotherapy in the NSMP molecular subgroup.",[102],"Endometrial Adenocarcinoma",[104,105,106],"Endometrial carcinoma","Molecular classification","Adjuvant therapy","2024-12-03",{"date":109,"type":110},"2024-12-06","ACTUAL",{"date":112,"type":110},"2022-02-08",{"date":114,"type":96},"2028-12-31",{"name":5,"class":6},1]